# STIMULAN®

# Case study

## Courtesy of Mr. Ramasubramanian Dharmarajan

Consultant Orthopaedic Surgeon, Cumbria, UK

### Clinical particulars

59-year-old female patient presented with infected well fixed total knee replacement two years after primary total knee replacement surgery. This was an acute presentation with all clinical features of infection with samples testing positive for Group B *Streptococcus*.

#### **Treatment**

First stage – radical debridement, implant removal and insertion of antibiotic-loaded cement spacer and STIMULAN mixed with vancomycin was used to fill the dead space and treat the infection.

Second stage – at 10 weeks, clinically soft tissues were healthy and intra-operative specimens were clear for organisms. Rotating hinge prosthesis was re-implanted.

### Outcome







First stage – Post-operative



Second stage – Post-operative



Second stage – Post-operative

For indications, contraindications, warnings and precautions see Instructions for Use. Concurrent use of locally administered antibiotics may affect setting time, absorption characteristics and/ or bone formation. It is the surgeon/healthcare professional's responsibility to give due consideration to the details in the medicinal product marketing authorisation in deciding whether it is appropriate for the patient under his/her care. The relevant Summary of Product Characteristics (SmPC) must be consulted. The type and dose of medicinal substance should also be assessed according to the individual patient's clinical circumstance.

This brochure may include the use of STIMULAN or techniques that go beyond the current clearance/approval granted by the relevant regulatory authority. Please contact your local representative for further information.

©2020, Biocomposites, STIMULAN, Bringing Calcium to Life, Power to Transform Outcomes and DRy26 are trademarks/registered trademarks of Biocomposites Ltd. All rights reserved. No unauthorised copying, reproduction, distributing or republication is allowed unless prior written permission is granted by the owner, Biocomposites Ltd.

Patents granted: GB2367552, EP I204599 BI, US 678039I, EP 259423I BI, US 88883063, CN ZL20I2I0466II7.X, GB24967I0, EP 3058899 BI, US I0390954 Patents pending: GBI502655.2, US I5/040075, CN 20I6I00897I0.5, GBI704688.9, EP I8275044.8, US I5/933936, CN I086I9579A

